Young-Jin Ko

Young-Jin Ko

Auto-generated profile, based on publicly available information

Young-Jin Ko

Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
YKYoung-Jin Ko
Young-Jin Ko
SKSeonji Kim
Seonji Kim
KPKyounghoon Park
Kyounghoon Park
MKMinsuk Kim
Minsuk Kim
BYBo Ram Yang
Bo Ram Yang
BPByung-Joo Park
Byung-Joo Park
Ko YJ, et al. J Korean Med Sci. 2018 May;33(23):e163. https://doi.org/10.3346/jkms.2018.33.e163

19 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JJJaehun Jung
Jaehun Jung
JIJae Hyoung Im
Jae Hyoung Im
YKYoung-Jin Ko
Young-Jin Ko
KHKyungmin Huh
Kyungmin Huh
CYChang-Gyo Yoon
Chang-Gyo Yoon
SYSeok-Jun Yoon
Seok-Jun Yoon
Surveillance remains an important tool for timely outbreak detection and response. Many countries, including Korea, have established national infectious disease surveillance systems with clinical notification. We aimed to evaluate the National Health Insurance Claims-based Surveillance (NHICS) compared to conventional passive report-based National Infectious Diseases Surveillance (NIDS). Reported to claimed cases ratios (R/C ratio) were evaluated from monthly notifiable disease cases captured by NIDS and NHICS. The relationships between 26 infectious diseases and each surveillance system were analysed using Pearson’s correlation analysis and linear regression. There was an overall increase in R/C ratio from 2010–2017 (0.37 to 0.78). In 22 infectious diseases, there was a correlation between NIDS and NHICS. Moreover, claim-based surveillance showed less fluctuating disease incidence rates than report-based surveillance for specific infectious diseases, such as varicella, mumps, and scarlet fever. However, for infectious diseases with episodic outbreaks or low incidence, it was difficult to assess NHICS usefulness. Claim-based surveillance is less affected by limitations of conventional report-based surveillance systems, such as reporting rate. Given delays in claim systems, a claim-based surveillance is expected to be complementary to conventional systems for the detection of various infectious diseases with the advancement of bio-information technology.

1 January 2019 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JJJaehun Jung
Jaehun Jung
YKYoung-Jin Ko
Young-Jin Ko
YKYoung-Eun Kim
Young-Eun Kim
KHKyungmin Huh
Kyungmin Huh
BPByung-Joo Park
Byung-Joo Park
SYSeok-Jun Yoon
Seok-Jun Yoon
Jung J, et al. J Korean Med Sci. 2019 Feb;34(7):e53. https://doi.org/10.3346/jkms.2019.34.e53

1 January 2019 in Therapeutic Advances in Drug Safety
Verified
Journal Article
Open access
PDF file
YKYoung-Jin Ko
Young-Jin Ko
SKSeonji Kim
Seonji Kim
KPKyounghoon Park
Kyounghoon Park
MKMinsuk Kim
Minsuk Kim
BYBo Ram Yang
Bo Ram Yang
BPByung-Joo Park
Byung-Joo Park
Background: In order to ensure safer use of non-vitamin K antagonist oral anticoagulants (NOACs), continuously detecting unexpected adverse drug reactions (ADRs) after market approval is necessary. Methods: We performed disproportionality analysis to evaluate association between ADRs and NOACs including apixaban, dabigatran, and rivaroxaban using data from the Korea Institute of Drug Safety and Risk Management–Korea Adverse Event Reporting System database (KIDS-KD) between 2012 and 2016. There was no significant signal other than bleeding when considering quantity, signal strength, seriousness, and causality. In order to evaluate the NOAC reports about bleeding, we selected 62 WHO-ART diagnostic codes associated with bleeding. Among the 26 codes that referred to major bleeding, 18 codes referred to gastrointestinal bleeding and 8 were referred to intracranial bleeding. We evaluated the significance of the signals using reporting odds ratios (RORs) adjusted for age and sex. Results: Treatments with apixaban, dabigatran, and rivaroxaban were associated with 1989, 1668, and 2960 adverse events, respectively. Any type of bleeding with apixaban, dabigatran, rivaroxaban, and warfarin was reported in 174 (8.8%), 209 (12.5%), 523 (17.8%), and 620 (9.5%) events, respectively. For any bleeding, adjusted RORs of apixaban, dabigatran, and rivaroxaban were 0.99 [95% confidence interval (CI): 0.83–1.17], 1.47 (95% CI: 1.25–1.75), and 2.48 (95% CI: 2.16–2.84), respectively. With respect to major bleeding, the adjusted RORs of apixaban, dabigatran, and rivaroxaban were 1.08 (95% CI: 0.82–1.41), 1.46 (95% CI: 1.10–1.90), and 1.82 (95% CI: 1.43–2.32), respectively. Conclusion: Rivaroxaban might have stronger association with bleeding than apixaban and dabigatran.

1 June 2018 in The Journal of Health Technology Assessment
Verified
Journal Article
Open access
JHJoonWoo Han
JoonWoo Han
YKYoung-Jin Ko
Young-Jin Ko
BPByung-Joo Park
Byung-Joo Park
SKSeonji Kim
Seonji Kim